Post-earnings recap
Reported
Fri, Feb 11, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a significant miss on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 7.45%. This could indicate that investors are optimistic about the company's long-term potential despite the disappointing earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.04 | N/A | -93.41% |
Management expressed concerns about the current performance but remains focused on future opportunities. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized their commitment to long-term growth despite short-term setbacks.